iOnctura raises €17.5M for pancreatic cancer therapy
iOnctura BV, a clinical-stage biotech developing novel cancer therapies, has been granted €17.5 million ($18.6…
December 20, 2022 - 2 minutes
iOnctura BV, a clinical-stage biotech developing novel cancer therapies, has been granted €17.5 million ($18.6…
Pancreatic cancer could be identified in patients up to three years earlier than current diagnoses,…
Biopharma company Antengene Corporation Limited says ATG-101, the company's in-house developed novel PD-L1/4-1BB bispecific antibody,…
Australian biotech company Noxopharm Limited has revealed encouraging new preclinical data from its long-term collaboration…